PDS Biotechnology

Historical price data

PDS Biotech is a clinical-stage company developing next-generation immunotherapies based on its proprietary Versamune® T-cell activating platform and PDS01ADC tumor-targeted IL-12. The company has generated compelling Phase 2 data in HPV-positive head and neck cancer, demonstrating significant tumor shrinkage and extended survival, and has now initiated a pivotal Phase 3 trial. Its strategy centers on advancing its lead asset, PDS0101, towards commercialization in HPV-associated cancers while exploring platform applications in other cancers and infectious diseases through strategic partnerships.

Versamune® is a cationic lipid nanoparticle platform that mimics an artificial virus to induce potent, antigen-specific CD4+ and CD8+ T-cell responses, while PDS01ADC is a tumor-targeted IL-12 immunocytokine designed to break down the immunosuppressive tumor microenvironment.